NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Expected to Announce Earnings of -$0.26 Per Share

Wall Street analysts predict that NeuBase Therapeutics, Inc. (NASDAQ:NBSEGet Rating) will announce earnings per share of ($0.26) for the current quarter, Zacks reports. Zero analysts have provided estimates for NeuBase Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.24) and the lowest estimate coming in at ($0.28). NeuBase Therapeutics posted earnings of ($0.24) per share during the same quarter last year, which would indicate a negative year over year growth rate of 8.3%. The company is expected to announce its next earnings results on Monday, January 1st.

On average, analysts expect that NeuBase Therapeutics will report full year earnings of ($0.97) per share for the current fiscal year, with EPS estimates ranging from ($1.09) to ($0.89). For the next financial year, analysts forecast that the firm will report earnings of ($1.17) per share, with EPS estimates ranging from ($1.31) to ($1.03). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover NeuBase Therapeutics.

NeuBase Therapeutics (NASDAQ:NBSEGet Rating) last released its earnings results on Thursday, February 10th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01.

NBSE has been the topic of a number of research reports. Zacks Investment Research upgraded NeuBase Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a research note on Wednesday, March 9th. HC Wainwright reaffirmed a “buy” rating on shares of NeuBase Therapeutics in a report on Monday, January 3rd.

Shares of NBSE stock traded down $0.01 on Friday, hitting $1.68. The stock had a trading volume of 200 shares, compared to its average volume of 133,254. The business has a 50 day moving average of $1.62 and a 200 day moving average of $2.53. NeuBase Therapeutics has a 12-month low of $1.21 and a 12-month high of $6.69. The stock has a market cap of $55.05 million, a price-to-earnings ratio of -1.72 and a beta of 0.53.

Large investors have recently added to or reduced their stakes in the business. AIGH Capital Management LLC bought a new position in NeuBase Therapeutics in the fourth quarter valued at $2,811,000. Millennium Management LLC grew its position in shares of NeuBase Therapeutics by 276.2% in the 2nd quarter. Millennium Management LLC now owns 174,020 shares of the company’s stock worth $834,000 after buying an additional 127,767 shares during the period. Morgan Stanley increased its position in NeuBase Therapeutics by 393.9% during the 2nd quarter. Morgan Stanley now owns 119,678 shares of the company’s stock valued at $574,000 after buying an additional 95,447 shares in the last quarter. Stonepine Capital Management LLC boosted its holdings in shares of NeuBase Therapeutics by 253.2% during the 3rd quarter. Stonepine Capital Management LLC now owns 109,742 shares of the company’s stock valued at $396,000 after acquiring an additional 78,672 shares during the last quarter. Finally, CM Management LLC bought a new position in shares of NeuBase Therapeutics during the 3rd quarter valued at $271,000. 31.22% of the stock is currently owned by hedge funds and other institutional investors.

NeuBase Therapeutics Company Profile (Get Rating)

NeuBase Therapeutics, Inc is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines.

Featured Stories

Get a free copy of the Zacks research report on NeuBase Therapeutics (NBSE)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for NeuBase Therapeutics (NASDAQ:NBSE)

Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with's FREE daily email newsletter.